Valuation: GlucoTrack, Inc.

Market Cap 2.06M 1.81M 1.7M 1.56M 2.91M 198M 2.94M 20.41M 7.92M 101M 7.73M 7.56M 327M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -1.88M -1.65M -1.55M -1.42M -2.66M -180M -2.68M -18.62M -7.22M -91.77M -7.05M -6.9M -298M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
89.83%
Yield 2024 *
-
Yield 2025 -
1 week+14.92%
Current month-39.29%
1 month-50.49%
3 months-52.80%
6 months-83.93%
Current year-95.56%
1 week 2
Extreme 1.9977
3.25
1 month 2
Extreme 1.9977
5.25
Current year 2
Extreme 1.9977
63.6
1 year 2
Extreme 1.9977
136.29
3 years 2
Extreme 1.9977
89,100.09
5 years 2
Extreme 1.9977
544,500.54
10 years 2
Extreme 1.9977
7,020,007.02
Manager TitleAgeSince
Chief Executive Officer 55 13/07/2026
Director of Finance/CFO 66 27/01/2025
Chief Operating Officer - 31/01/2025
Director TitleAgeSince
Director/Board Member 56 24/08/2023
Chairman 64 12/02/2024
Director/Board Member 78 13/06/2024
Date Insider Type Main position Quantity % Market Cap. Importance
26/03/25 Free

Director

4,490 0.0431%
25/03/25 Free

Director

8,747 0.0840%
25/03/25 Free

Director

5,473 0.0526%
Change 5-day change 1-year change 3-year change Capi.($)
+27.09%+14.92%-97.00%-99.99% 1.62M
+1.46%+5.87%+5.75%+33.71% 47.56B
+2.67%+2.31%+47.50%+38.37% 44.09B
-1.38%+3.42%+9.39%+88.88% 41.5B
+4.78%+2.01%+352.12%+566.20% 40.88B
-0.62%+0.11%+1.12%+46.02% 29.67B
+0.56%+0.67%+25.08%+155.71% 17.23B
+2.05%+4.04%+24.47%+41.67% 15.06B
+3.39%-6.86% - - 14.65B
+7.38%+17.54%-2.25% - 13.82B
Average +0.90%-0.34%+40.69%+108.82% 26.45B
Weighted average by Cap. +0.94%+0.96%+71.88%+147.49%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.86M -18.71M -17.1M -31.95M -2.17B -32.22M -224M -86.88M -1.1B -84.84M -82.99M -3.59B -19.39M -17.04M -16.05M -14.67M -27.42M -1.86B -27.65M -192M -74.54M -948M -72.79M -71.21M -3.08B
Net Debt -5.35M -4.7M -4.43M -4.05M -7.57M -513M -7.63M -53.04M -20.57M -261M -20.09M -19.65M -850M -3.94M -3.46M -3.26M -2.98M -5.57M -378M -5.61M -39.03M -15.14M -192M -14.78M -14.46M -625M
Logo GlucoTrack, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
24/09/26 US$2.580 +27.09% 51,008,435
23/09/26 US$2.030 -8.56% 27,578,694
22/09/26 US$2.220 -3.48% 540,022
21/09/26 US$2.300 -6.88% 38,813
18/09/26 US$2.470 +3.78% 27,723
  1. Stock Market
  2. Stocks
  3. GCTK Stock